Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.

Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN.

J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9.

2.

Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod.

Berrong Z, Mkrtichyan M, Ahmad S, Webb M, Mohamed E, Okoev G, Matevosyan A, Shrimali R, Abu Eid R, Hammond S, Janik JE, Khleif SN.

Cancer Immunol Res. 2018 Feb;6(2):201-208. doi: 10.1158/2326-6066.CIR-17-0223. Epub 2018 Jan 5.

PMID:
29305519
3.

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.

Shrimali RK, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, Gittelman RM, Yusko E, Sanders C, Robins H, Hammond SA, Janik JE, Mkrtichyan M, Gupta S, Khleif SN.

Cancer Immunol Res. 2017 Sep;5(9):755-766. doi: 10.1158/2326-6066.CIR-17-0292.

PMID:
28848055
4.

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.

Shrimali R, Ahmad S, Berrong Z, Okoev G, Matevosyan A, Razavi GSE, Petit R, Gupta S, Mkrtichyan M, Khleif SN.

J Immunother Cancer. 2017 Aug 15;5(1):64. doi: 10.1186/s40425-017-0266-x.

5.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

6.

Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition.

Abu Eid R, Ahmad S, Lin Y, Webb M, Berrong Z, Shrimali R, Kumai T, Ananth S, Rodriguez PC, Celis E, Janik J, Mkrtichyan M, Khleif SN.

Cancer Res. 2017 Aug 1;77(15):4135-4145. doi: 10.1158/0008-5472.CAN-16-1925. Epub 2017 Jun 14.

PMID:
28615225
7.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

8.

Free Lung Cancer Screening Trends Toward a Twofold Increase in Lung Cancer Prevalence in the Underserved Southeastern United States.

Simmerman EL, Thomson NB 3rd, Dillard TA, Hao Z, Sadek RF, Khleif SN, Schroeder C.

South Med J. 2017 Mar;110(3):188-194. doi: 10.14423/SMJ.0000000000000619.

PMID:
28257543
9.

Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.

Ahmad S, Abu-Eid R, Shrimali R, Webb M, Verma V, Doroodchi A, Berrong Z, Samara R, Rodriguez PC, Mkrtichyan M, Khleif SN.

Cancer Res. 2017 Apr 15;77(8):1892-1904. doi: 10.1158/0008-5472.CAN-16-1839. Epub 2017 Jan 20.

10.

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.

Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Galon J, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM.

J Immunother Cancer. 2016 Jun 21;4:37. doi: 10.1186/s40425-016-0142-0. eCollection 2016.

11.

Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed.

Abu Eid R, Razavi GS, Mkrtichyan M, Janik J, Khleif SN.

Cancer Immunol Res. 2016 May;4(5):377-82. doi: 10.1158/2326-6066.CIR-16-0048. Epub 2016 May 1. Review.

12.

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells.

Zdanov S, Mandapathil M, Abu Eid R, Adamson-Fadeyi S, Wilson W, Qian J, Carnie A, Tarasova N, Mkrtichyan M, Berzofsky JA, Whiteside TL, Khleif SN.

Cancer Immunol Res. 2016 Apr;4(4):354-65. doi: 10.1158/2326-6066.CIR-15-0241. Epub 2016 Feb 15.

13.

The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them.

Finn OJ, Khleif SN, Herberman RB.

Cancer Prev Res (Phila). 2015 Nov;8(11):1011-6. doi: 10.1158/1940-6207.CAPR-15-0234. Epub 2015 Sep 9.

14.

Programmed death-1 & its ligands: promising targets for cancer immunotherapy.

Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN.

Immunotherapy. 2015;7(7):777-92. doi: 10.2217/imt.15.49. Epub 2015 Aug 7. Review.

PMID:
26250412
15.

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+ T-cell proliferation and survival.

Abu Eid R, Friedman KM, Mkrtichyan M, Walens A, King W, Janik J, Khleif SN.

Oncoimmunology. 2015 Feb 3;4(5):e1005448. eCollection 2015 May.

16.

Preamble to the 2015 SITC immunotherapy biomarkers taskforce.

Butterfield LH, Disis ML, Fox BA, Khleif SN, Marincola FM.

J Immunother Cancer. 2015 Mar 24;3:8. doi: 10.1186/s40425-015-0052-6. eCollection 2015.

17.

Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.

Rahma OE, Herrin VE, Ibrahim RA, Toubaji A, Bernstein S, Dakheel O, Steinberg SM, Abu Eid R, Mkrtichyan M, Berzofsky JA, Khleif SN.

J Transl Med. 2014 Dec 16;12:353. doi: 10.1186/s12967-014-0353-4.

18.

The international cancer expert corps: a unique approach for sustainable cancer care in low and lower-middle income countries.

Coleman CN, Formenti SC, Williams TR, Petereit DG, Soo KC, Wong J, Chao N, Shulman LN, Grover S, Magrath I, Hahn S, Liu FF, DeWeese T, Khleif SN, Steinberg M, Roth L, Pistenmaa DA, Love RR, Mohiuddin M, Vikram B.

Front Oncol. 2014 Nov 19;4:333. doi: 10.3389/fonc.2014.00333. eCollection 2014. Review.

19.

Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.

Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Berzofsky JA, Friedman KM, Mkrtichyan M, Khleif SN.

Cancer Immunol Res. 2014 Nov;2(11):1080-9. doi: 10.1158/2326-6066.CIR-14-0095. Epub 2014 Jul 30.

20.

Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.

Rahma OE, Gammoh E, Simon RM, Khleif SN.

Clin Cancer Res. 2014 Sep 15;20(18):4758-67. doi: 10.1158/1078-0432.CCR-13-2671. Epub 2014 Jul 18.

21.

Ovarian cancer from an immune perspective.

Zakharia Y, Rahma O, Khleif SN.

Radiat Res. 2014 Aug;182(2):239-51. doi: 10.1667/RR13741.1. Epub 2014 Jul 18. Review.

PMID:
25036981
22.

Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells.

Chen Z, Ozbun L, Chong N, Wallecha A, Berzofsky JA, Khleif SN.

Cancer Immunol Res. 2014 Sep;2(9):911-22. doi: 10.1158/2326-6066.CIR-13-0197. Epub 2014 May 28.

23.

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.

Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, Steinberg SM, Khleif SN.

J Transl Med. 2014 Feb 24;12:55. doi: 10.1186/1479-5876-12-55.

24.

Molecular characterization of antigen-peptide pulsed dendritic cells: immature dendritic cells develop a distinct molecular profile when pulsed with antigen peptide.

Yang AX, Chong N, Jiang Y, Catalano J, Puri RK, Khleif SN.

PLoS One. 2014 Jan 27;9(1):e86306. doi: 10.1371/journal.pone.0086306. eCollection 2014.

25.

The regulatory landscape for actively personalized cancer immunotherapies.

Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U.

Nat Biotechnol. 2013 Oct;31(10):880-2. doi: 10.1038/nbt.2708. No abstract available.

PMID:
24104749
26.

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.

Mkrtichyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J, Khleif SN.

J Immunother Cancer. 2013 Aug 29;1:15. doi: 10.1186/2051-1426-1-15. eCollection 2013.

27.

Cancer classification using the Immunoscore: a worldwide task force.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

J Transl Med. 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205. Review.

28.

B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.

Mkrtichyan M, Najjar YG, Raulfs EC, Liu L, Langerman S, Guittard G, Ozbun L, Khleif SN.

J Immunol. 2012 Sep 1;189(5):2338-47. doi: 10.4049/jimmunol.1103085. Epub 2012 Jul 25.

29.

Therapeutic vaccines for gastrointestinal cancers.

Rahma OE, Khleif SN.

Gastroenterol Hepatol (N Y). 2011 Aug;7(8):517-64.

30.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

31.

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.

Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN.

Cancer Immunol Immunother. 2012 Mar;61(3):373-84. doi: 10.1007/s00262-011-1100-9. Epub 2011 Sep 17.

32.

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms.

Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN.

Eur J Immunol. 2011 Oct;41(10):2977-86. doi: 10.1002/eji.201141639. Epub 2011 Aug 17.

33.

Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.

Meyskens FL Jr, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E; C-Change Chemoprevention Clinical Trials and Biomarkers Subcommittee.

Cancer Prev Res (Phila). 2011 Mar;4(3):311-23. doi: 10.1158/1940-6207.CAPR-09-0014.

34.

Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.

Butterfield LH, Disis ML, Khleif SN, Balwit JM, Marincola FM.

J Transl Med. 2010 Dec 7;8:130. doi: 10.1186/1479-5876-8-130.

35.

AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.

Khleif SN, Doroshow JH, Hait WN; AACR-FDA-NCI Cancer Biomarkers Collaborative.

Clin Cancer Res. 2010 Jul 1;16(13):3299-318. doi: 10.1158/1078-0432.CCR-10-0880. Epub 2010 May 25.

36.

A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.

Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN.

J Transl Med. 2010 Jan 28;8:8. doi: 10.1186/1479-5876-8-8.

37.

HPV as a model for the development of prophylactic and therapeutic cancer vaccines.

Samara RN, Khleif SN.

Curr Mol Med. 2009 Aug;9(6):766-73. Review.

PMID:
19689303
38.

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM.

J Transl Med. 2009 Jun 17;7:45. doi: 10.1186/1479-5876-7-45.

39.

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM.

J Transl Med. 2008 Dec 23;6:81. doi: 10.1186/1479-5876-6-81.

40.

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.

Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F, Khleif SN.

Cancer Immunol Immunother. 2008 Sep;57(9):1413-20. doi: 10.1007/s00262-008-0477-6. Epub 2008 Feb 23.

PMID:
18297281
41.

The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection.

Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson RM, Berzofsky JA, Khleif SN.

Vaccine. 2007 Aug 1;25(31):5882-91. Epub 2007 Jun 12.

PMID:
17602804
42.

Jordan palliative care initiative: a WHO Demonstration Project.

Stjernswärd J, Ferris FD, Khleif SN, Jamous W, Treish IM, Milhem M, Bushnaq M, Al Khateib A, Al Shtiat MN, Wheeler MS, Alwan A.

J Pain Symptom Manage. 2007 May;33(5):628-33. Review.

PMID:
17482059
43.

Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism.

Ibrahim R, Frederickson H, Parr A, Ward Y, Moncur J, Khleif SN.

Cancer. 2006 Mar 1;106(5):1065-77.

44.

Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.

Qian J, Dong Y, Pang YY, Ibrahim R, Berzofsky JA, Schiller JT, Khleif SN.

Int J Cancer. 2006 Jun 15;118(12):3022-9.

45.

Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth.

Dong Y, Qian J, Ibrahim R, Berzofsky JA, Khleif SN.

J Immunother. 2006 Jan-Feb;29(1):32-40.

PMID:
16365598
46.

Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Khleif SN.

Curr Treat Options Oncol. 2003 Apr;4(2):111-9. Review.

PMID:
12594937
47.

The role of vaccines in cancer prevention.

Khleif SN, Frederickson H.

Cancer Treat Res. 2001;106:283-306. Review. No abstract available.

PMID:
11225007
48.

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.

Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J.

J Immunother. 1999 Mar;22(2):155-65.

PMID:
10093040
49.

Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.

Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J.

Cell Immunol. 1997 Dec 15;182(2):137-51.

PMID:
9514698
50.

Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function.

Otterson GA, Chen Wd, Coxon AB, Khleif SN, Kaye FJ.

Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12036-40.

Supplemental Content

Loading ...
Support Center